Probes For Detection Of Animal Nucleotide Sequences Patents (Class 536/24.31)
  • Patent number: 11857531
    Abstract: Provided herein are compositions and methods for the treatment of conditions such as benign prostatic hyperplasia (BPH), Lower Urinary Tract Symptoms (LUTS), chronic prostatitis (CP) and/or chronic pelvic pain syndrome (CPPS). In particular, provided herein are combination therapies comprising a mast cell inhibitor and a histamine receptor antagonist.
    Type: Grant
    Filed: August 5, 2021
    Date of Patent: January 2, 2024
    Assignee: Northwestern University
    Inventors: Praveen Thumbikat, Anthony J. Schaeffer
  • Patent number: 11846639
    Abstract: Compositions and methods are provided for the identification of peptide sequences that are ligands for a T cell receptor (TCR) of interest, in a given MHC context.
    Type: Grant
    Filed: July 16, 2021
    Date of Patent: December 19, 2023
    Assignees: The Board of Trustees of the Leland Stanford Junior University, CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Michael Edward Birnbaum, Juan Luis Mendoza, Michael Thomas Bethune, David Baltimore, Kenan Christopher Garcia
  • Patent number: 11848073
    Abstract: A system for indexing, updating, and search haplotypes for genetic genealogical discovery in genotype databases. The system includes a pool of genetic indexes, a haplotype ingestion engine, and a haplotype query engine. The haplotypes of a number of individuals in a genotype database are indexed by a pool of multiple panels, and each panel pool can be dynamically updated by the insertion or deletion of individual haplotypes. A genetic genealogical search of a query haplotype against the database is achieved by first projecting the query onto a subset of panels in the pool, then conducting long match queries over each panel, and finally aggregating the identified long matches into Identical-by-Descent segments, i.e., DNA matches, between the query and the haplotypes in the database.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: December 19, 2023
    Assignees: University of Central Florida Research Foundation, Inc., The Board of Regents of the University of Texas System
    Inventors: Degui Zhi, Shaojie Zhang, Ardalan Naseri, Ahsan Sanaullah, Erwin Holzhauser
  • Patent number: 11803967
    Abstract: Various methods and systems are provided for bicuspid valve detection with ultrasound imaging. In one embodiment, a method comprises acquiring ultrasound video of a heart over at least one cardiac cycle, identifying frames in the ultrasound video corresponding to at least one cardiac phase, and classifying a cardiac structure in the identified frames as a bicuspid valve or a tricuspid valve. A generative model such as a variational autoencoder trained on ultrasound image frames at the at least one cardiac phase may be used to classify the cardiac structure. In this way, relatively rare occurrences of bicuspid aortic valves may be automatically detected during regular cardiac ultrasound screenings.
    Type: Grant
    Filed: April 1, 2021
    Date of Patent: October 31, 2023
    Assignee: GE Precision Healthcare LLC
    Inventors: Pavan Annangi, Rahul Venkataramani, Deepa Anand, Eigil Samset
  • Patent number: 11771776
    Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.
    Type: Grant
    Filed: July 8, 2022
    Date of Patent: October 3, 2023
    Assignee: Dyne Therapeutics, Inc.
    Inventors: Romesh R. Subramanian, Mohammed T. Qatanani, Timothy Weeden, Cody A. Desjardins, Brendan Quinn, John Najim
  • Patent number: 11713485
    Abstract: The disclosure provides a method for detecting a target analyte in a biological sample including contacting the sample with one or more probe sets each comprising a primary probe and a linker, contacting the sample with an initiator sequence, contacting the sample with a plurality of fluorescent DNA hairpins, wherein the probe binds the target molecule, the linker connects the probe to the initiator sequence, and wherein the initiator sequence nucleates with the cognate hairpin and triggers self-assembly of tethered fluorescent amplification polymers, and detecting the target molecule by measuring fluorescent signal of the sample.
    Type: Grant
    Filed: August 3, 2021
    Date of Patent: August 1, 2023
    Assignee: President and Fellows of Harvard College
    Inventors: Evan R. Daugharthy, George M. Church
  • Patent number: 11708415
    Abstract: IL33 antagonists alone or in combination with IL-4R antagonists can be used to treat or inhibit eosinophilic asthma, eosinophilic COPD, eosinophilic ACOS, and nasal polyps in a subject having one or more risk alleles in the intronic IL1RL1 variant rs1420101, in the IL33 variant rs1342326, in both, or in variants in linkage disequilibrium thereof.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: July 25, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Shannon Bruse, Shane McCarthy, Aris Baras, Frederick Dewey, Omri Gottesman
  • Patent number: 11683315
    Abstract: Sharing data is disclosed. In some cases, sharing data includes receiving a request to share data from a first account to a second account, receiving an indication of a plurality of first account profiles associated with the first account to share with the second account, and establishing sharing from the plurality of first account profiles to the second account, wherein sharing comprises the second account having read access to a subset of nonpublic data associated with the plurality of first account profiles.
    Type: Grant
    Filed: October 12, 2021
    Date of Patent: June 20, 2023
    Assignee: 23andMe, Inc.
    Inventors: Brian Lee Hawthorne, Oleksiy Khomenko, Jeffrey Mellen, Marcela Miyazawa, Michael Polcari, Jack Tihon, Alexander Wong, Anne Wojcicki, Linda Avey
  • Patent number: 11667919
    Abstract: Methods of treating cancer are provided along with nucleic acids and nucleic acid analog sequences of a long-non-coding RNA (lncRNA), and reagents useful for knocking down the lncRNA.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: June 6, 2023
    Assignee: University of Pittsburgh—of the Commonwealth System of Higher Education
    Inventors: Da Yang, Zehua Wang
  • Patent number: 11610647
    Abstract: The invention relates to a method for generating a unique identifier of a subject from a genotyped DNA sample from said subject, the method comprising the steps of: obtaining a number N?2 of genomic positions of interest, said obtained genomic positions being such that, in a population of M subjects, these genomic positions exhibit a polymorphism of at least one nucleotide having an allelic frequency of between 25% and 35%, for the minority allele; combining in pairs the obtained genomic positions by means of logical functions so as to obtain a binary code bc.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: March 21, 2023
    Inventors: Denis Pierron, Thierry Letellier, Margit Heiske, Veronica Pereda
  • Patent number: 11485966
    Abstract: The present invention provides a method for improving the loading of nucleic acid on a solid support by contacting the solid support with a poloxamer-containing reagent. The present invention also provides a method for improving the stability of a nucleic acid on a solid support, comprising contacting a nucleic acid molecule with a partially double-strand oligonucleotide before or after loading the nucleic acid molecule on a solid support, so as to cause the nucleic acid molecule to hybridize with the oligonucleotide. The present invention also provides a combined use of the two methods.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: November 1, 2022
    Inventors: Hui Wang, Xun Xu, Jin Yang, Ao Chen, Chongjun Xu, Wenwei Zhang
  • Patent number: 11414666
    Abstract: The present invention provides a method and a pharmaceutical composition for the treatment of the NDO comprising the viral expression vector carrying a transcription cassette that harbors transgene(s) inhibiting/silencing neurotransmission or synaptic transmission of afferent neurons.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: August 16, 2022
    Inventors: François Giuliano, Alberto Epstein, Olivier Le Coz, Alejandro Aranda
  • Patent number: 11406691
    Abstract: The invention provides an AMH-INH-GNIH tri-expression gene vaccine capable of improving fecundity of animals and a preparation method of engineering strain thereof. The engineering strain was deposited in China Center for Type Culture Collection on Aug. 15, 2018, with deposit No.: CCTCC NO:M 2018544. When the engineering strain is used for direct immunization of animals or immunization of animals after being mixed with DNA vaccine adjuvant, the fecundity of the animals can be effectively improved. The tri-expression gene is a tri-expression non-resistant DNA plasmid of Mullerian duct resisting hormone, inhibin and gonadotropin release restraining hormone, which can be used for direct immunization of the animals through mucosa immunization to generate antibodies in the manner of being sprayed to noses, orally administered, blended into feeds and the like.
    Type: Grant
    Filed: September 18, 2020
    Date of Patent: August 9, 2022
    Assignee: Huazhong Agricultural University
    Inventors: Liguo Yang, Jiaomei Tang, Qunli Zhou, Aixin Liang, Aizhen Guo
  • Patent number: 10378016
    Abstract: The invention provides aptamer-gene modulator conjugates, where the aptamer and the gene modulator are linked together. The invention further provides a method for cell-specific delivery of gene modulators to hard to transfect cells such as CD4+ cell.
    Type: Grant
    Filed: December 6, 2011
    Date of Patent: August 13, 2019
    Assignee: Children's Medical Center Corporation
    Inventors: Judy Lieberman, Lee Adam Wheeler
  • Patent number: 9752187
    Abstract: The present application describes methods for accurate and cost-effective categorization of DNA samples into different types of in vitro generated DNA or different types of natural DNA such as from different tissues and/or physiological/pathological states. The invention achieves categorization by comparing “signal ratios” that are correlated to ratios of methylation levels at specific genomic loci, but does not rely on calculation of actual methylation levels at any genomic locus. Therefore the disclosed inventive method eliminates the requirement for external DNA species and controls, thereby simplifying and increasing the accuracy of the assay. The described inventive technology also enables performing the categorization of DNA together with DNA profiling in the same reaction, thereby allowing for concomitant categorization and determination of identity of the samples.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: September 5, 2017
    Assignee: Nucleix
    Inventors: Adam Wasserstrom, Danny Frumkin
  • Patent number: 9730979
    Abstract: The present invention provides methods for modulating SET activity by contacting SET with a binding agent such as an ApoE peptide derivative. In one embodiment of the invention, a pharmaceutical composition capable of modulating SET activity is administered to a patient for the treatment of an inflammatory or neurological condition. In another embodiment of the invention, compounds efficacious for the treatment of inflammatory and neurological conditions are identified by screening for a binding agent capable of competing with or inhibiting the binding of an ApoE derivative to SET.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: August 15, 2017
    Assignee: COGNOSCI, INC.
    Inventors: Michael P. Vitek, Dale J. Christensen, Jessica Oddo
  • Patent number: 9173943
    Abstract: The present invention relates to imprinted polymer nanoparticles. In particular, the present invention provides imprinted polymer nanoparticles polymerized in the presence of a target molecule (e.g., peptide), wherein the imprinted polymer nanoparticles comprise vinyl, acryl, and/or methacryl monomers, wherein the monomers have affinity for the target molecule. The present invention also relates to methods of using imprinted polymer nanoparticles in biomacromolecular purification methods (e.g., to purify monoclonal antibodies or hormones), in toxin elimination methods (e.g., hemoperfusion), in diagnostics, in research, as well as in therapeutic methods (e.g., therapeutic methods where antisera or monoclonal antibodies are normally employed).
    Type: Grant
    Filed: January 11, 2010
    Date of Patent: November 3, 2015
    Assignee: The Regents of the University of California
    Inventors: Yu Hoshino, Kenneth J. Shea
  • Patent number: 9145449
    Abstract: The present invention is directed toward pharmaceutical compositions comprising an isolated polypeptide and a pharmaceutically acceptable carrier. The present invention also discloses an antibody or an antigen-binding portion thereof that bind to the isolated polypeptide. Methods of inhibiting cancer cells growth are also disclosed, comprising administering the isolated polypeptide or the antibody described herein to a subject in need thereof.
    Type: Grant
    Filed: February 4, 2014
    Date of Patent: September 29, 2015
    Inventors: Tzu-Hao Wang, Chia-Lung Tsai, Angel Chao
  • Patent number: 9145561
    Abstract: The present invention provides compositions and methods for regulating expression of nucleotide sequences in fungi. Compositions are novel nucleotide sequences for a tissue preferred promoter isolated from the Agaricus bisporus lectin gene. The sequences drive expression preferentially to fruit body tissue. A method for expressing a nucleotide sequence in fungi using the regulatory sequences disclosed herein is provided. The method comprises transforming a fungal cell to comprise a nucleotide sequence operably linked to one or more of the regulatory sequences of the present invention and regenerating a stably transformed fungus from the transformed cell.
    Type: Grant
    Filed: August 30, 2011
    Date of Patent: September 29, 2015
    Assignee: Interexon Corporation
    Inventors: Zhixin Shi, Jack Q. Wilkinson, Donald S. Walters, C. Peter Romaine
  • Patent number: 9140707
    Abstract: A method for generating antibodies preferable to either a normal protein and a mutated form of the normal protein, respectively, where a mutation associated with the mutated form includes either a single point mutation or a small number of point mutations where the method includes creating first and second antigenic peptides of a predetermined length corresponding respectively to common regions of the normal target protein and the mutated form, where the common regions are identical to one another except for the point mutation of the mutated form, obtaining first and second antibodies by multiplying the first and second antigenic peptides via hybridoma methods, and identifying the respective affinities of the first and second antibodies for the normal target protein and the mutated form. Also included are methods of using the first and second antibodies to detect and quantify respective amounts of a normal target protein and a mutated form of the target protein.
    Type: Grant
    Filed: August 10, 2007
    Date of Patent: September 22, 2015
    Assignee: University of Louisville Research Foundation, Inc.
    Inventors: Kyung Aih Kang, Stephen Peiper
  • Patent number: 9063139
    Abstract: Methods for identifying a subject at risk for developing AMD are disclosed, as are kits which can be used to practice the methods. The methods include identifying specific protective or risk polymorphisms or genotypes from the subject's genetic material, including polymorphisms in the BF, C2 and/or CFH genes. Microarrays and kits for use in these methods are also provided.
    Type: Grant
    Filed: August 2, 2011
    Date of Patent: June 23, 2015
    Assignees: The Trustees of Columbia University in the City of New York, University of Iowa Research Foundation, The United States of America, As Represented By the Secretary of the Department of Health and Human Services
    Inventors: Rando L. Allikmets, Gregory S. Hageman, Michael C. Dean, Albert M. Gold
  • Publication number: 20150141287
    Abstract: Genetic markers associated with intellectual disability as well as compositions, methods and kits for screening for genetic markers of intellectual disability, diagnosing intellectual disability and identifying individuals with a predisposition for offspring suffering from intellectual disability are provided.
    Type: Application
    Filed: January 22, 2015
    Publication date: May 21, 2015
    Inventor: John B. Vincent
  • Publication number: 20150141277
    Abstract: A method for the measurement of the amount or difference in the amounts of 2 or more nucleic acid targets in a sample, the method comprising the steps of attaching to nucleic acids present in the sample (1) a tag which allows the nucleic acids to be captured to a solid support; and (2) a labelled probe for a first nucleic acid target present in the sample and a labelled probe for second nucleic acid target present in the sample, and then measuring the amount of each labelled probe or difference in the amount of labelled probes; wherein the probe is not a single labelled nucleotide.
    Type: Application
    Filed: May 17, 2013
    Publication date: May 21, 2015
    Inventors: Edwin Southern, Dietrich Lueerssen, Oliver Miller, Natalie Milner
  • Publication number: 20150141391
    Abstract: The present disclosure relates to methods of determining a treatment course of action. In particular, the present disclosure relates to mutations in the gene encoding estrogen receptor and their association with responsiveness to estrogen therapies for cancer.
    Type: Application
    Filed: October 14, 2014
    Publication date: May 21, 2015
    Inventors: Arul M. Chinnaiyan, Dan Robinson, Yi-Mi Wu
  • Patent number: 9034837
    Abstract: The present invention provides compositions and methods of treatment of HCV infected subjects that are not sensitive to interferon treatment. Further, compositions and methods are provided for prevention of organ transplant rejection. The compositions of the invention comprise an anti microRNA-122 oligonucleotide, and are made for administration to a primate.
    Type: Grant
    Filed: April 26, 2010
    Date of Patent: May 19, 2015
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Elisabeth S. Hildebrandt-Eriksen, Andreas Petri, Sakari Kauppinen, Niels Abrahamsen, Robert Eldon Lanford
  • Patent number: 9035036
    Abstract: Disclosed herein are methods and reagents for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) targeting treatment. The detection of these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: May 19, 2015
    Assignees: The General Hospital, Dana-Farber Cancer Institute, Inc.
    Inventors: Daphne Winifred Bell, Daniel A. Haber, Pasi Antero Janne, Bruce E. Johnson, Thomas J. Lynch, Matthew Meyerson, Juan Guillermo Paez, William R. Sellers, Jeffrey E. Settleman, Raffaella Sordella
  • Publication number: 20150133333
    Abstract: Disclosed are kits and methods for diagnosing a person with, or assessing a person's risk for developing, sarcoidosis and/or complicated sarcoidosis.
    Type: Application
    Filed: September 11, 2014
    Publication date: May 14, 2015
    Inventors: Joe G.N. Garcia, Tong Zhou, Wei Zhang, Roberto Machado
  • Patent number: 9029084
    Abstract: A polynucleotide primer comprising at least the final six nucleotides of one of the following primer sequences, or a sequence complementary thereto: SEQ. ID NOS. 1 to 18, 21 to 45 or 74 to 77.
    Type: Grant
    Filed: April 4, 2006
    Date of Patent: May 12, 2015
    Assignee: Qiagen Manchester Limited
    Inventors: David Mark Whitcombe, Nicola Jo Thelwell, Paul Francis Ravetto
  • Publication number: 20150125868
    Abstract: The present invention relates to a method for diagnosing a myeloid cancer in a subject, which comprises the step of analyzing a biological sample from said subject by determining the presence or the absence of a mutation in the ASXL1 (additional sex combs like 1) gene coding for the polypeptide having the sequence SEQ ID No 2. A kit for diagnosing myeloid cancer in a subject comprising at least one nucleic acid probe or oligonucleotide or at least one antibody, which can be used in a such a method.
    Type: Application
    Filed: October 10, 2014
    Publication date: May 7, 2015
    Applicants: Qiagen Marseille SA, Institut Paoli-Calmettes, INSERM (Institut National de la Santé et de la Recherche Médicale)
  • Publication number: 20150126399
    Abstract: The present invention provides nucleic acid sequences that are used for identification, classification and diagnosis of specific types of cancers. The nucleic acid sequences can also be used for prognosis evaluation of a subject based on the expression pattern of a biological sample.
    Type: Application
    Filed: January 8, 2015
    Publication date: May 7, 2015
    Inventors: Ranit Aharonov, Nitzan Rosenfeld, Hila Benjamin
  • Publication number: 20150118155
    Abstract: The present invention provides a method of diagnosing the existence or risk of hyperthyroidism in a feline comprising measuring the level of expression of one or more biomarkers selected from the group consisting of e.g., IYD, TG, SLC5A5, NIS, TPO, TSHR, DUOX1, DUOX2 (ThOX), TGFB1, CSTD, DCN and SEPP1 and the expression products thereof, in a biological sample from the feline, wherein elevated expression of the one or more biomarkers in the sample relative to a control value for expression in a sample from a normal feline or feline population, or a baseline value from the feline, indicates the existence or risk of hyperthyroidism; a method of treating a feline so diagnosed; and compositions, reagents and kits for carrying out the specified methods.
    Type: Application
    Filed: June 14, 2012
    Publication date: April 30, 2015
    Applicant: Hill's Pet Nutrition, Inc.
    Inventors: Samer Al-Murrani, Xiangming Gao
  • Publication number: 20150110733
    Abstract: The present invention provides a method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of: (i) determining a genotype of the subject at a location corresponding to the location of one or more single nucleotide polymorphisms (SNPs) selected from the group consisting of: Group 1, (ii) identifying the subject as a predicted responder to glatiramer acetate if the genotype of the subject contains one or more A alleles at the location of Group 2, one or more C alleles at the location of Group 3, one or more G alleles at the location of Group 4, or one or more T alleles at the location of kgp18432055, kgp279772, kgp3991733 or kgp7242489; and (iii) administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the subject only if the subject is identif
    Type: Application
    Filed: October 21, 2014
    Publication date: April 23, 2015
    Inventors: Amir TCHELET, Michael HAYDEN, Liat HAYARDENY, Colin James Douglas ROSS, Iris GROSSMAN, David LADKANI
  • Patent number: 9012619
    Abstract: Detection probes are provided that are capable of detecting a sequence to be detected containing a mutation even when a sequence not to be detected containing no mutation coexists with the sequence to be detected containing a mutation, which are different only in a single base from each other. At least one oligonucleotide selected from the group consisting of SEQ ID NOs: 2˜16 is used as a probe. Even in a sample containing an abl gene in which a mutation has occurred and an abl gene in which no mutation has occurred, the use of such probes in, for example, Tm analysis allows the mutation to be detected.
    Type: Grant
    Filed: February 19, 2008
    Date of Patent: April 21, 2015
    Assignee: Arkray, Inc.
    Inventors: Mitsuharu Hirai, Satoshi Majima, Taira Maekawa, Shinya Kimura
  • Patent number: 9006199
    Abstract: Treatment of prostate cancer by regional and prolonged release of one or more nucleotide-based RNAi agents is provided.
    Type: Grant
    Filed: November 14, 2012
    Date of Patent: April 14, 2015
    Assignee: Silenseed Ltd.
    Inventors: Amotz Shemi, Elina Zorde Khvalevsky, Rachel Malka Gabai
  • Publication number: 20150099747
    Abstract: The invention comprises reagents and methods for detecting cancer-associated mutations in the human EZH2 gene. Further, a method of detecting the mutations and a method of treatment are disclosed.
    Type: Application
    Filed: October 7, 2014
    Publication date: April 9, 2015
    Inventors: Xiaoju Max Ma, Chitra Manohar, Alison Tsan
  • Patent number: 8999648
    Abstract: A system (100) for classifying a biological test sample, including a database (112) populated with reference expression data. The reference expression data includes expression levels of a plurality of molecules (polynucleotides or polypeptides), including a set of marker molecules, in a plurality of reference samples. Each reference sample has a pre-assigned value for each of one or more clinically significant variables. The system includes at least one processor (110) and at least one storage medium containing program instructions for execution by said processor (110). The program instructions cause the processor to accept (122) input expression data including a test vector of expression levels of the marker molecules in the biological test sample; and pass the input expression data to one or more analysis programs (130a, 130b, 35).
    Type: Grant
    Filed: September 30, 2010
    Date of Patent: April 7, 2015
    Assignee: Signal Genetics, Inc.
    Inventor: Ryan Van Laar
  • Patent number: 9000144
    Abstract: In Caenorhabditis elegans, lin-4 and let-7 encode 22- and 21-nucleotide RNAs, respectively, that function as key regulators of developmental timing. Because the appearance of these short RNAs is regulated during development, they are also referred to as “small temporal RNAs” (stRNAs). We show that many more 21- and 22-nt expressed RNAs, termed microRNAs, (miRNAs), exist in invertebrates and vertebrates, and that some of these novel RNAs, similar to let-7 stRAN, are also highly conserved. This suggests that sequence-specific post-transcriptional regulatory mechanisms mediated by small RNAs are more general than previously appreciated.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: April 7, 2015
    Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
    Inventors: Thomas Tuschl, Mariana Lagos-Quintana, Winfried Lendeckel, Jutta Dammann, Reinhard Rauhut
  • Patent number: 9000142
    Abstract: There is disclosed a photocleavable sense-antisense nucleobase polymer complex capable of modulating gene expression comprising an unnatural antisense nucleobase polymer that targets an mRNA, and a photocleavable sense nucleobase polymer noncovalently bound to the antisense nucleobase polymer, wherein the photocleavable sense nucleobase polymer comprises a plurality of nucleobase polymers connected by a photocleavable linkage. There is also disclosed a method for controlling the time and spatial position of gene expression comprising selecting a target mRNA, introducing the photocleavable sense-antisense nucleobase polymer complex into a cell, and selectively irradiating the cell with light.
    Type: Grant
    Filed: June 23, 2009
    Date of Patent: April 7, 2015
    Assignee: Syntrix Biosystems, Inc.
    Inventor: John A. Zebala
  • Publication number: 20150094231
    Abstract: Provided are oligonucleotides that are capable of detecting KRAS and PIK3CA mutations in both cancer patients and healthy individuals with high specificity in kPCR assays. When the oligonucleotides are used as forward primers in conjunction with a defined genotyping algorithm spreadsheet, the primers are capable of enhancing detection of KRAS codon 12, 13, and 61 and PIK3CA codon 542, 545, and 1047 single nucleotide polymorphisms (SNPs) in a background of wild-type sequences. The oligonucleotides of the present invention are also capable of preventing pseudogene amplification when the oligonucleotides are hybridized as reverse primers or detection probes to the mismatch sequences.
    Type: Application
    Filed: December 12, 2014
    Publication date: April 2, 2015
    Inventors: Jill Detmer, Arejas J. Uzgiris, Andy Ying
  • Publication number: 20150088430
    Abstract: The invention in some aspects provides methods of determining the likelihood that a subject has lung cancer based on the expression of informative-genes. In other aspects, the invention provides methods for determining an appropriate diagnostic intervention plan for a subject based on the expression of informative-genes. Related compositions and kits are provided in other aspects of the invention.
    Type: Application
    Filed: April 26, 2013
    Publication date: March 26, 2015
    Inventor: Duncan H. Whitney
  • Patent number: 8987435
    Abstract: The present invention provides oligomeric compounds and uses thereof. In certain embodiments, such oligomeric compounds are useful as antisense compounds. Certain such antisense compounds are useful as RNase H antisense compounds or as RNAi compounds.
    Type: Grant
    Filed: October 23, 2009
    Date of Patent: March 24, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Eric E. Swayze, Balkrishen Bhat, Walter F. Lima, Thazha P. Prakash, Garth A. Kinberger
  • Patent number: 8987222
    Abstract: The present invention relates to the discovery of (SNPs) significantly associated with Huntington's disease (HD). The present invention utilizes RNA silencing technology (e.g. RNAi) against such SNPs optimally combined with select additional SNP targeting silencing agents, thereby resulting in an effective treatment of significantly-sized patient populations. Silencing agents having enhanced discriminatory properties are also featured.
    Type: Grant
    Filed: April 8, 2010
    Date of Patent: March 24, 2015
    Assignee: University of Massachusetts
    Inventors: Neil Aronin, Edith Pfister, Phillip D. Zamore
  • Publication number: 20150080235
    Abstract: Described herein are compositions and methods for diagnosing or monitoring type 1 diabetes.
    Type: Application
    Filed: September 18, 2014
    Publication date: March 19, 2015
    Inventor: Sahar Usmani-Brown
  • Publication number: 20150072345
    Abstract: Oligonucleotides with a novel sugar-phosphate backbone containing at least one 2?-arabino-fluoronucleoside and an internucleoside 3?-NH—P(—O)(OR)—O-5? linkage, where R is a positively charged counter ion or hydrogen, and methods of synthesizing and using the inventive oligonucleotides are provided. The inventive phosphoramidate 2?-arabino-fluorooligonucleotides have a high RNA binding affinity to complementary nucleic acids and are base and acid stable.
    Type: Application
    Filed: September 11, 2014
    Publication date: March 12, 2015
    Inventors: Sergei M. Gryaznov, Ronald G. Schultz
  • Publication number: 20150074836
    Abstract: The invention concerns nucleic acids coding for mutated or truncated forms of the human parkin gene, or forms comprising multiplication of exons, and the corresponding proteins and antibodies. The invention also concerns methods and kits for identifying mutations of the parkin gene, and for studying compounds for therapeutic purposes.
    Type: Application
    Filed: August 7, 2014
    Publication date: March 12, 2015
    Applicants: Aventis Pharma S.A., Institut National de la Santé et de la Recherche Médicale
    Inventors: Alexis Brice, Christophe Lucking, Patrice Denefle
  • Patent number: 8975237
    Abstract: Treatment of fibrosis and fibrotic diseases, disorders, and conditions, and associated methods, compositions, formulations and articles.
    Type: Grant
    Filed: December 22, 2008
    Date of Patent: March 10, 2015
    Assignee: CoDa Therapeutics, Inc.
    Inventors: David L. Becker, Colin R. Green, Bradford James Duft
  • Publication number: 20150065380
    Abstract: The present invention relates to epilepsy-inducing brain somatic mutations which are associated with intractable epilepsy caused by malformations of cortical development, and uses thereof. More particularly, the present invention relates to an mTOR (Mammalian target of rapamycin) gene having mutations in a nucleotide sequence or an mTOR protein having mutations in an amino acid sequence resulting from the mutations in the nucleotide sequence. Further, the present invention relates to a technique for diagnosing intractable epilepsy caused by malformations of cortical development using the gene or the protein.
    Type: Application
    Filed: September 2, 2014
    Publication date: March 5, 2015
    Inventors: Jeong Ho LEE, Dong Seok Kim, Hoon Chul Kang, Jae Seok Lim, Woo-II Kim
  • Publication number: 20150065378
    Abstract: Synthetic oligonucleotides that comprise a nucleic acid binding protein binding site, PCR primer sequences, and tag sequences that do not bind to nucleic acid binding proteins, with a total length of 85-130 nucleotides are disclosed herein. Also disclosed are libraries and kits comprising the synthetic oligonucleotides as well as methods of detecting nucleic acid binding proteins in a sample using the synthetic oligonucleotides.
    Type: Application
    Filed: August 28, 2014
    Publication date: March 5, 2015
    Inventors: William Mathers, Zheng Ye
  • Patent number: 8962582
    Abstract: The present application relates to the use of hybridization chain reaction (HCR) to form double stranded RNA polymers in the presence of a target, such as a nucleic acid associated with a disease or disorder. The RNA polymers are preferably able to activate the RNA-dependent kinase PKR. Activation of PKR via RNA-HCR can be used to treat a wide variety of diseases and disorders by specifically targeting diseased cells.
    Type: Grant
    Filed: June 7, 2011
    Date of Patent: February 24, 2015
    Assignee: California Institute of Technology
    Inventors: Robert Dirks, Niles A. Pierce
  • Publication number: 20150051084
    Abstract: A method for determining the prognosis of prostate cancer in a subject is provided which comprises the assessment of the methylation status of the HSPB1 gene in a prostate cancer sample.
    Type: Application
    Filed: March 19, 2013
    Publication date: February 19, 2015
    Inventors: Attila Lorincz, Natasa Vasiljevic, Amar Ahmad